Multiple myelorna （MM） is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the respo...Multiple myelorna （MM） is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression-free survival （PFS）, and overall survival （OS） of MM patients, However, alongside these benefits, a significant increased risk of developing secondary primary malignancies （SPMs） has been observed. Until now, there has not been a relevant large study of Chinese MM patients available to study SPMs, and no secondary malignancy after bortezomib treatment alone has been reported.展开更多
基金This study partly supported by the National Natural Science Foundation of China （No.81670192）.
文摘Multiple myelorna （MM） is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression-free survival （PFS）, and overall survival （OS） of MM patients, However, alongside these benefits, a significant increased risk of developing secondary primary malignancies （SPMs） has been observed. Until now, there has not been a relevant large study of Chinese MM patients available to study SPMs, and no secondary malignancy after bortezomib treatment alone has been reported.
